Brief: UCB Presents Bimzelx Data At Eular 2026
03/06/2026 07:04
BRIEF-UCB Presents Bimzelx Data At Eular 2026 June 3 (Reuters) - Ucb SA UCB.BR:
UCB: BIMZELX DATA AT EULAR 2026 SHOW EARLY AND SUSTAINED INFLAMMATION CONTROL CAN IMPROVE PATIENT REPORTED OUTCOMES AND LIMIT DISEASE PROGRESSION IN PSA AND AXSPA
EARLY BIMEKIZUMAB TREATMENT ASSOCIATED WITH REDUCED RADIOGRAPHIC PROGRESSION IN PSA OVER THREE YEARS
SUBSTANTIAL IMPACT ON MRI INFLAMMATION AND STRUCTURAL LESIONS IN NR-AXSPA WITH BIMEKIZUMAB
Source text: tinyurl.com/4s426w85
Further company coverage: UCB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on UCB SA
See all newsEurope Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside
Brief: UCB Says CIMZIA Delivered Consistent Effect In Rheumatoid Arthritis
Brief: UCB Said Dapirolizumab Pegol Shows Potential To Reduce Flare Rates
Brief: UCB Presents Bimzelx Data At Eular 2026